首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   280篇
  免费   11篇
  国内免费   5篇
儿科学   8篇
妇产科学   7篇
基础医学   19篇
口腔科学   13篇
临床医学   29篇
内科学   98篇
皮肤病学   6篇
神经病学   4篇
特种医学   46篇
外科学   25篇
综合类   8篇
预防医学   10篇
眼科学   1篇
药学   13篇
  1篇
肿瘤学   8篇
  2023年   2篇
  2022年   3篇
  2021年   8篇
  2020年   3篇
  2019年   4篇
  2018年   5篇
  2017年   2篇
  2016年   5篇
  2015年   6篇
  2014年   4篇
  2013年   6篇
  2012年   10篇
  2011年   7篇
  2010年   10篇
  2009年   7篇
  2008年   16篇
  2007年   9篇
  2006年   15篇
  2005年   14篇
  2004年   14篇
  2003年   5篇
  2002年   4篇
  2001年   4篇
  1999年   3篇
  1998年   8篇
  1997年   10篇
  1996年   16篇
  1995年   11篇
  1994年   11篇
  1993年   11篇
  1992年   4篇
  1991年   2篇
  1990年   2篇
  1989年   4篇
  1988年   8篇
  1987年   5篇
  1986年   9篇
  1985年   2篇
  1984年   2篇
  1983年   3篇
  1982年   4篇
  1981年   5篇
  1980年   4篇
  1979年   1篇
  1978年   1篇
  1977年   1篇
  1976年   1篇
  1975年   2篇
  1970年   1篇
  1968年   1篇
排序方式: 共有296条查询结果,搜索用时 15 毫秒
101.
102.
In October 2022, an outbreak in Europe of highly pathogenic avian influenza (HPAI) A(H5N1) in intensively farmed minks occurred in northwest Spain. A single mink farm hosting more than 50,000 minks was involved. The identified viruses belong to clade 2.3.4.4b, which is responsible of the ongoing epizootic in Europe. An uncommon mutation (T271A) in the PB2 gene with potential public health implications was found. Our investigations indicate onward mink transmission of the virus may have occurred in the affected farm.  相似文献   
103.
中国大陆地区妇女骨质疏松筛选工具探讨   总被引:3,自引:0,他引:3  
目的建立适用于中国大陆地区40岁及以上妇女的骨质疏松(osteoporosis,OP)筛选工具。方法以20~39岁妇女腰椎骨密度的均数和标准差作为参考值计算T—score。以双能X线骨密度仪(dual—energy X—ray absorptiometry,DxA)的测量结果作为金标准,采用二分类的Bayes判别分析,建立判别函数。结果我国大陆地区40岁及以上妇女OP筛选工具(osteoporosis screening tool for Chinese,OSTC)为:体重-2×年龄+50。判别准则为OSTC〉0为无OP危险性,OSTC≤0为有OP危险性。OSTC的正判率为75.78%,灵敏度为76.8%,特异度为75.1%,Kappa值为0.51(P=0.000),说明OSTC与DXA的判定结果一致性尚可。结论OSTC是一个简便的OP筛选工具。根据年龄、体重两个变量的简单计算,即可对我国大陆地区40岁及以上的妇女进行OP危险性的筛选。但OSTC没有得到外部数据的验证,其优劣还有待进一步评价。  相似文献   
104.
Mosesson  MW; Nesheim  ME; DiOrio  J; Hainfeld  JF; Wall  JS; Mann  KG 《Blood》1985,65(5):1158-1162
We studied purified bovine factor V (mol wt 330,000) by scanning transmission electron microscopy (STEM) of freeze-dried unstained or negatively contrasted preparations. Freeze-dried molecules revealed discrete shapes ranging from roughly spheroidal (100 to 120 nm) to oblong (140 to 200 nm in length X 50 to 100 nm in width). Oblong shapes could often be resolved into two or three distinct domains, ranging from 60 to 100 nm in diameter. A "satellite" nodular structure (30 to 50 nm in diameter) connected to the main molecule by a thin stalk (approximately 10 nm wide) up to 80 nm in length was occasionally seen. Glutaraldehyde-treated preparations yielded the same shapes as were seen in unfixed preparations but revealed better definition of submolecular features and "satellite" nodules. STEM mass analysis confirmed that each of the different shapes represented a monomolecular form of factor V. Negatively stained images revealed objects having the same general shapes as freeze-dried molecules, although greater detail was evident. Some images suggested that molecules consist of five or more discrete parts. Taken together, these observations indicate that factor V molecules are multidomainal, flexible structures that tend to have an irregular oblong shape with an axial ratio between 3:2 and 2:1.  相似文献   
105.
STUDY OBJECTIVE: To analyse the relationship between menstrual and reproductive factors and the risk of low bone mineral density (BMD). DESIGN: This was a population based screening programme carried out between 1991 and 1993 among 1373 perimenopausal women in northern Italy by means of dual photon absorptiometry at the lumbar spine. MAIN RESULTS: BMD was strongly related to the age at menopause. In comparison with women reporting menopause below 45 years of age, the odds ratios (OR) of being in the lowest compared with the highest BMD tertile were 0.7 (95% confidence interval (CI) 0.3,1.5) and 0.3 (95% CI 0.1,0.8), respectively, in those with menopause at age 45-49 and above 50 years: the trend in risk was significant. Likewise, the risk of being in the lowest tertile increased with years since the menopause. Compared with women who reported they had undergone the menopause less than two years before interview, the OR of being in the lowest BMD tertile were 2.1 (95% CI 1.1,4.3), 2.3 (95% CI 1.1, 5.0), and 5.7 (95% CI 2.5,12.9) respectively in women who reported menopause 2-5, 6-9, and > or = 10 years earlier. The protective effect on bone density of late age at menopause was observed in different strata of years since menopause. Likewise, the increasing risk of a low BMD with increasing years since the menopause was evident in strata of different age at menopause. No relationships were observed between BMD and the age at menarche, characteristics of menstrual cycles, and the duration of menses. Likewise, no association emerged between reproductive history, including parity and age at first pregnancy, and BMD. CONCLUSIONS: In this Italian population the risk of being in the lowest BMD tertile decreased with increasing age at menopause and increased with years since menopause. No relationships emerged between BMD and other menstrual characteristics or reproductive factors.  相似文献   
106.
Two novel preparatory regimens for conditioning of patients with leukemia for allogeneic bone marrow transplantation (BMT) from histocompatible sibling donors have been tested in a phase III trial under the auspices of the Southwest Oncology Group (SWOG 8612). These two regimens consisted either of fractionated total body irradiation and etoposide (FTBI/VP-16) or high-dose busulfan with cyclophosphamide (BU/CY). Only patients who had failed prior conventional management at least once were study eligible, ie, no patients with acute leukemia in first remission (CR) or in first chronic phase (CP) of chronic myelogenous leukemia (CML) participated. Patients were stratified according to the following risk criteria: "good-risk" patients were those who were in second CR of their acute leukemia or in accelerated phase (AP) of CML; "poor-risk" patients had further advanced stages of leukemia. During a 52-month period, 131 patients were registered of whom 122 (93%) were study eligible. Sixty-one eligible patients were randomized to the FTBI/VP-16 arm and 61 to the BU/CY regimen. Of these 122 patients, 114 (93%) proceeded to BMT according to protocol. Posttransplant immunosuppression to prevent graft-versus-host disease (GVHD) consisted of cyclosporine and prednisone (CSA/PSE). Neither overall survival nor disease-free survival (DFS) differed significantly between the two treatment groups (P = .89 and .69, respectively). Estimated DFS for "good-risk" patients who had been prepared with the FTBI/VP-16 regimen was 55% +/- 11%, as compared with patients treated with BU/CY whose DFS figure was 34% +/- 10% (P = .30). For "poor-risk" candidates, the DFS rates at 24 months were 17% +/- 6% (for FTBI/VP-16) and 24% +/- 8% (for BU/CY), respectively (P = .81). These figures do not differ significantly, especially in view of the fact that the "good- risk" patients prepared with the FTBI/VP-16 regimen were younger than those treated with BU/CY. Both regimens were well tolerated with no regimen-related deaths encountered during the 6-week period after BMT. This study also confirmed the efficacy of the CSA/PSE combination in the prevention of GVHD with 23 of 113 (20%) of BMT recipients developing moderate to severe acute GVHD. The leading cause for treatment failure was leukemic relapse (45 of the 114 BMT recipients suffered a recurrence of their leukemia), whereas 38 patients died without evidence of relapse. Thirty-one patients are alive and in continued CR after marrow transplantation; four are alive in relapse.(ABSTRACT TRUNCATED AT 400 WORDS)  相似文献   
107.
108.
本文以人红细胞(RBC)胞浆提取物为SSA抗原来源,探讨了免疫印迹法(IBT)检测抗SSA抗体的可能性及特点。结果显示,在RBC-IBT中有两条抗SSA(干燥综合征抗原)抗体特异性酶染色带,分子量分别为52KD和60KD。非特异性染色带极少或无。也未见其它几种常一自身抗体(抗SM、RNP、SSB等)的显色带。这说明RBC-IBT对抗SSA抗体的检测有高度的专一性和特异性,值得推荐。文中还就RBC-IBT法中主要的实验影响因素进行了探讨。  相似文献   
109.
110.
Isolation and characterization of an acquired antithrombin antibody   总被引:4,自引:1,他引:3  
Lawson  JH; Pennell  BJ; Olson  JD; Mann  KG 《Blood》1990,76(11):2249-2257
A 68-year-old man, following mitral valve replacement, presented with a low-grade chronic consumptive coagulopathy. Laboratory analysis showed mild fibrinolysis, minimal effect of coumadin therapy, and a prolonged thrombin time (greater than 150 seconds using bovine IIa). When purified human IIa was used the thrombin time normalized to within 17 seconds of controls, suggesting a possible inhibitor of bovine IIa. An anti-IIa antibody was isolated by protein A-Sepharose (Sigma, St Louis, MO) chromatography followed by affinity chromatography using a bovine IIa-Sepharose column. The effects of this purified anti-IIa antibody on both bovine and human IIa procoagulant and anticoagulant functions were studied. The isolated immunoglobulin G (IgG) was observed to inhibit bovine IIa in all assays tested. This IgG was also able to slightly prolong fibrinogen clotting by human IIa. Using an enzyme-linked immunosorbent assay it was observed that the IgG bound to bovine IIa, bovine II, human IIa, but not to human II. Further, binding was detectable at approximately 50-fold lower concentrations to bovine IIa (1 nmol/L IgG concentration) than to human IIa (50 nmol/L IgG concentration). The effect of the antibody on the reaction between IIa and AT III/heparin was investigated. Human IIa was found to be protected from AT III/heparin neutralization in the presence of this antibody. These results suggest that this patient developed an antibody that strongly binds to and inhibits the bovine IIa in all assays tested. However, the antibody only significantly affects human IIa neutralization by AT III/heparin, and has little effect on the human IIa procoagulant activity. These data suggest that the decreased effect of AT III/heparin on this patient's IIa may have been a contributing factor in his coagulopathy. The exact cause of this antibody development is unclear, but the role of bovine topical thrombin used during cardiac valve replacement surgery is suspect.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号